Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions

Area of Science:

• Oncology
• Gastroenterology

Background:

• Gallbladder cancer (GBC) represents the most frequent primary tumor within biliary tract cancers (BTC), contributing significantly to cancer incidence and mortality.
• Key risk factors include female sex, advanced age, ethnicity, and chronic gallbladder inflammation.

Purpose of the Study:

• To review the current treatment landscape for gallbladder cancer (GBC), encompassing surgical, chemotherapeutic, and novel therapeutic strategies.
• To highlight the challenges in early diagnosis and the limited curative options available for advanced stages.

Main Methods:

• Literature review of existing studies on GBC epidemiology, risk factors, and treatment modalities.
• Analysis of current standards of care, including neoadjuvant therapy, adjuvant treatment, and palliative chemotherapy regimens like gemcitabine/cisplatin and FOLFOX.
• Exploration of emerging therapies such as PD-L1 inhibitors and targeted therapies based on molecular profiling.

Main Results:

• Surgery offers curative potential only for a small fraction (10%) of early-stage GBC patients.
• Neoadjuvant treatment can enable secondary surgical treatment in up to one-third of locally advanced cases.
• Palliative chemotherapy (gemcitabine/cisplatin) is standard for advanced GBC, with FOLFOX as a second-line option; PD-L1 inhibitors and targeted therapies show promise.

Conclusions:

• The prognosis for GBC remains challenging due to late diagnosis and limited effective treatments for advanced stages.
• Advances in immunotherapy (PD-L1 inhibitors) and targeted therapy, guided by molecular profiling, offer new avenues to improve outcomes for GBC patients.
• Further research into molecular differences and personalized treatment strategies is crucial for enhancing GBC patient prognosis.